Congrats to a fantastic carreer driven by very relevant clinical questions and publications. Your legacy will be strong Assistance Publique – Hôpitaux de Paris (AP-HP) as well as for the #IBD field, dear Laurent.

The 2024 #NobelPrize in Physiology or Medicine focuses on the discovery of a vital regulatory mechanism used in cells to control gene activity. Genetic information flows from DNA to messenger RNA (mRNA), via a process called transcription, and then on to the cellular machinery

New online! Interpreting modern randomized controlled trials of medical therapy in inflammatory bowel disease go.nature.com/3YeNfpz

"Consensus Statements on Assessments and Vaccinations Prior to Commencement of Advanced Therapies for the Treatment of Inflammatory Bowel Diseases" free to read at bit.ly/3ZXdgeo #GItwitter #IBD #consensus

Comparative Efficacy of Biologics and Small Molecule in Ulcerative Colitis: A Systematic Review and Network Meta-analysis - Clinical Gastroenterology and Hepatology cghjournal.org/article/S1542-…

Nobel Prize winning concepts land in IBD. The discovery of power and importance of microRNA biology . Bruce E. Sands presenting the long term results of the phase 2a Obefazimod UC. Study . Is this the game changer? Calling all investigators . We need to get the phase III DONE !!!

🌟 Making a choice of therapy for IBD Take into account extraintestinal concerns as well as contraindications to treatment! 🙏🏻 David T. Rubin, MD #GITwitter #ACG2024 ACG

#ECCO UC Treatment Guideline Update - how it started... Bram Verstockt Stefan Holubar MD MS Raja Atreya Irina Blumenstein Alaa El-Hussuna Manuel Barreiro Anthony de Buck Fernando Gomollón Massimo Fantini MD, PhD Federica Mariangela Allocca Pascal Juillerat MD MSc, IBD specialist María José Casanova Uri Kopylov Piotr Eder et al. #IBD

IBD Monitoring how&when. Tandem talk with #HagarBanaiEran from #rabinhospitalpetahtikva at #FalkSymposium238 in Florence. ⁦Humanitas University⁩

Luc Biedermann at #Falksymposium238 presenting on biological treatments in EoE. Luc Biedermann , Great job.

How can you not love Charles Bernstein ? Amazing career as a clinician scientist for over 30 years!!! Linking the learnings from IBD epidemiology to climate inform clinical practice Gil Kaplan MD MPH Edward Loftus

Just published in the American Journal of Therapeutics 🔥 JAKi in Chronic Inflammatory Pouch Conditions: 📌Clinical response: 43% 📌Endoscopic response: 48% 📌AEs: 16% 📌Primary treatment failure: 42% 📊JAKi are not recommended to be first line treatment in chronic pouch

Completely agree ! Amazing meeting and conclusions, congratulations! Edward Loftus Millie Long Miguel Regueiro Corey Siegel Stephen B. Hanauer, MD #AIBD2024

Mucosal Healing With Vedolizumab in Patients With Chronic Pouchitis: EARNEST, a Randomized, Double-Blind, Placebo-Controlled Trial ➡️ ow.ly/qY1950UX0ZO

Just Starting 4th Postgraduate Course #ECCO2025 #EDUCOM course with more than 350 attendees! Uri Kopylov Fernando Magro with and a amazing talk from Severine Vermeire

New IBD classification. Florence classification Dr Dermot McGovern IBD at Cedars-Sinai #ECCO2025

Thank you for your contribution to this Great case discussion and long Life to the PG of ECCO ! Manuel Barreiro Iago Rodriguez-Lago Uri Kopylov #ECCO2025

Appendicectomy plus standard medical therapy versus standard medical therapy alone for maintenance of remission in ulcerative colitis (ACCURE): a pragmatic, open-label, international, randomised trial - The Lancet Gastroenterology & Hepatology thelancet.com/journals/langa…

We’re pleased to announce the “ECCO-ESGAR-ESP-IBUS Guideline on Diagnostics and Monitoring of Patients with IBD,” a project involving IBUS, showing the role of IUS in the diagnosis and monitoring of IBD patients. P.1: 10.1093/ecco-jcc/jjaf106 P.2: 10.1093/ecco-jcc/jjaf107

'Free to read' via bit.ly/45GWWRG "Global Consensus Statement on the Management of Pregnancy in Inflammatory Bowel Disease" by Mahadevan et al #IBD #GItwitter #pregnancy